19.65 +0.28 (1.45%)
After hours: 5:36PM EDT
|Bid||18.99 x 3000|
|Ask||19.65 x 200|
|Day's Range||18.27 - 19.38|
|52 Week Range||3.21 - 21.95|
|PE Ratio (TTM)||-19.39|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||19.00|
NEW YORK, NY / ACCESSWIRE / October 19, 2017 / Shares of both Spectrum Pharmaceuticals and Protalix BioTherapeutics were on fire in Wednesday trading after the companies announced good news respectively. ...
NEW YORK, NY / ACCESSWIRE / October 18, 2017 / The Dow Jones Industrial Average crossed the 23,000 plateau for the first time ever on Tuesday as investors digested the latest batch of corporate earnings. ...
Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the oral presentation of interim data from a Phase 2 clinical study evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer by scientists from the MD Anderson Cancer Center which was presented in Yokohama, ...
DALLAS, TX / ACCESSWIRE / October 10, 2017 / Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI): COMPANY DESCRIPTION Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is focused on the acquisition, development ...
Spectrum Pharmaceuticals, Inc. today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.75% Convertible Senior Notes due December 15, 2018 .